NEWS RELEASE - For Immediate Release

Journal of Inflammation Article Demonstrates Utility of V-Sense in Drug Development

July 20, 2012 - Pittsburgh, Pennsylvania

Celsense, Inc. announced today the publication of an article in the Journal of Inflammation describing the use of V-Sense to image and measure changes in inflammation in an experimental model of rheumatoid arthritis. V-Sense, a perfluorocarbon tracer agent, labels leukocytes in situ rendering them visible using magnetic resonance imaging (MRI). Leukocytes participating in an inflammatory event can be imaged and quantified in their anatomical context over time. The article, authored by investigators at Celsense, demonstrates that V-Sense can be used as a quantitative biomarker of response to therapeutic intervention in an arthritis model.

V-Sense’s unique ability to image inflammation has been demonstrated by a number of academic researchers in a variety of disease models, including organ transplant rejection, peripheral nerve inflammation, infection, and inflammatory bowel disease. “What is new in this publication is not only the application to arthritis, but a demonstration that an existing measure of disease could be correlated with the V-Sense data. In addition, this approach can directly detect a mediator of disease prior to the development of irreversible damage to tissues due to the inflammatory process,” said Dr. Amy Wesa, Director of Research and Development at Celsense.

The online version of the article is available at http://www.journal-inflammation.com/content/pdf/1476-9255-9-24.pdf.

About V-Sense
V-Sense is a proprietary perfluorocarbon emulsion. V-Sense is safe for direct intravenous injection for preclinical studies. Following injection, the emulsion droplets are internalized by circulating monocytes and macrophage. These labeled cells accumulate at inflammatory sites in vivo and are detected by fluorine-19 (19F) MRI, or alternatively, by NMR in excised tissue. Quantification of the 19F signal yields a fast, accurate marker of the degree of inflammation present that is directly proportional to the macrophage/monocyte tissue burden.  V-Sense can be used to detect a wide range of lesions and diseases where inflammation is a hallmark, such as cancer and infections, and autoimmune diseases. V-Sense is also used for pharmacological safety profiling to detect ‘off target’ inflammatory side effects in preclinical drug screens.

About Celsense, Inc.
Celsense, Inc. offers products that enable the non-invasive imaging of inflammation and transplanted cells using MRI. The mission of the company is to be the standard for cellular imaging in human health.

Celsense, Inc. markets three reagent families for MRI of cells for discovery, pre-clinical research and translational medicine.  The company also offers the Voxel Tracker ® software for visualizing and quantifying cells in MRI data sets. Customers include leading pharmaceutical and biotechnology companies and biomedical research centers worldwide. 

Contact Information:

Charlie O’Hanlon, President and CEO
Celsense, Inc.
(412) 263-2870